Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
Complete Title: A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Trial Phase: I/II
Investigator: Mazyar Shadman
Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL
Keywords:
- Leukemia, Lymphoid
- Waldenstrom Macroglobulinemia
- Lymphoma, Mantle-Cell
- Lymphoma, B-Cell
- Lymphoma, Small Lymphocytic (SLL)
- Lymphoma, B-Cell Non-Hodgkin
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
Mazyar Shadman
RG1121830
NCT05360238
A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Leukemia, Lymphoid
Waldenstrom Macroglobulinemia
Lymphoma, Mantle-Cell
Lymphoma, B-Cell
Lymphoma, Small Lymphocytic (SLL)
Lymphoma, B-Cell Non-Hodgkin